| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1385 | Chlorokojic Acid | Antiviral and antifungal agent |
|
| DCC1386 | Chlorphenoctium Amsonate | Widely used biocidal agent |
|
| DCC1387 | Chlorphentermine | Sympathomimetic agent, facilitating the release of catecholamines, especially noradrenaline and dopamine, from nerve terminals in the brain and also inhibiting their uptake |
|
| DCC1388 | Chlorphentermine Hydrochloride | Serotonin transporter substrate |
|
| DCC1389 | Chm-1-p-na | Hydrophilic prodrug of CHM-1 |
|
| DCC1390 | Chmfl-btk-01 | Novel potent and highly selective irreversible Brutons tyrosine kinase (BTK) inhibitor, inhibiting BTK Y223 auto-phosphorylation |
|
| DCC1391 | Chmfl-flt3-122 | Potent and selective FLT3 inhibitor |
|
| DCC1392 | Chmfl-flt3-335 | Novel Potent Fms-like Tyrosine Kinase 3 Internal Tandem Duplications (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia |
|
| DCC1393 | Chmfl-kit-64 | Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors |
|
| DCC1394 | Choerospondin | Antioxidant; Aldose reductase inhibitor |
|
| DCC1395 | Chondrillasterol | Natural phytosterol, showing antidiabetes activities |
|
| DCC1396 | chromafenozide | Potent and selective partial agonist of ecdysone receptor (EcR) |
|
| DCC1397 | Chromenone 1 | Novel potent BMP potentiator with osteogenic efficacy, enhancing canonical BMP outputs at the expense of TGFβ-Smads in an unprecedented manner |
|
| DCC1398 | Chrysotoxine | Novel inhibitor of 6-hydroxydopamine induced apoptosis in SH-SY5Y cells via mitochondria protection and NF-κB modulation |
|
| DCC1399 | Chs-111 | Novel inhibitor of superoxide anion (O2(-)) generation; Inhibitor of phospholipase D activation; Modulator of immune cell migration via RhoA activity inhibition; Inhibitor of Rac2 activation in stimulated neutrophils |
|
| DCC1400 | Chu-128 | Novel Non-peptide GLP-1R Agonist, adopting a unique binding mode with a more open receptor conformation at the extracellular face |
|
| DCC1401 | Chymase-in-1 | Novel chymase inhibitor, exhibiting concentration-dependent chymase inhibitory activity |
|
| DCC1402 | Ciap1-in-d19-14 | Novel inhibitor of E3 ligase activity of cIAP1, antagonizing c-MYC by stabilizing MAD1 protein in cells |
|
| DCC1403 | Cic-37 | Novel SOCE modulator, displaying selectivity over other calcium channels, such as TRPV1, TRPM8, and voltage-operated calcium channels |
|
| DCC1404 | cicletanine | Stimulator of nitric oxide release and scavenger of superoxide |
|
| DCC1405 | Cid-1011163 | Novel Selective Agonist of GPR55 |
|
| DCC1406 | Cid-1252842 | Novel Selective Agonist of GPR55 |
|
| DCC1407 | Cid-1304264 | HIV-1 Rev pre-integration inhibitor |
|
| DCC1408 | Cid15997213 | Novel specific anti-VEEV (Anti-Venezuelan Equine Encephalitis Virus) agent |
|
| DCC1409 | Cid-16672637 | Novel inhibitor against the NS3/4A serine protease of Hepatitis C virus genotype 3 |
|
| DCC1410 | Cid-1792579 | Novel Selective Agonist of GPR55 |
|
| DCC1411 | Cid21480113 | Antibacterial agent, being effective in treating dapsone resistant leprosy |
|
| DCC1412 | Cid-2995007 | Blocker of integrin binding to its endothelial receptor (VCAM-1) |
|
| DCC1413 | Cid-44216842 | Novel inhibitor of Cdc42 that act by blocking nucleotide binding with no effect on RhoA or Rac |
|
| DCC1414 | Cid44271905 | Novel lopinavir analogue against COVID-19, forming the most stable complex with the Mpro |
|
